retatrutide safety study 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in Phase 3 Trial New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most RETATRUTIDE | NEOPEPS

While compounding is strictly limited to the preparation of medicines for individual patients based on a valid prescription, the facility was found to be manufacturing and marketing GIP/GLP-1-based products, including semaglutide, tirzepatide, and combination formulations, for broader commercial distribution, particularly for weight management purposes

Significant findings included up to a 30.3% average weight loss at 80 weeks a result comparable to bariatric surgery outcomes

Retatrutide is not yet commercially available

N Engl J Med 2020;383(15):1425e35

What makes this different from oral semaglutide: no fasting window, no water restrictions, any time of day